关于MIBC患者SHR-A2102注射与adebrelimab结合的临床研究(SHR-1316)
SHR-A2102的随机,开放,多中心II/III期临床研究与肌动术治疗肌肉运动治疗(MIBC)的围手术期治疗(SHR-1316)(SHR-1316)(SHR-1316)
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Yanyan Lu
- 电话号码:+86-518-82342973
- 邮箱:yanyan.lu.yl87@hengrui.com
研究联系人备份
- 姓名:Xiaoning Han
- 电话号码:+86-518-82342973
- 邮箱:xiaoning.han@hengrui.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 招聘中
- Fudan University Shanghai Cancer Center
-
首席研究员:
- Dingwei Ye
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18-80 years old, gender not limited.
- The patient voluntarily joined this study and signed informed consent.
- ECOG score is 0 or 1.
- Expected survival period ≥ 2 years.
- Pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer.
- There are assessable lesions that meet the RECIST 1.1 criteria.
- Enough organ function.
Exclusion Criteria:
- Received systemic anti-tumor therapy 4 weeks before starting the study treatment.
- The toxicity and/or complications of previous anti-tumor treatments have not recovered to NCI-CTCAE ≤ 1 level.
- Subjects known or suspected to have interstitial pneumonia.
- Individuals with any active, known or suspected autoimmune diseases.
- There are clinical symptoms or diseases of the heart that have not been well controlled.
- Diagnosed with any other malignant tumor.
- Subjects who have experienced severe infections within 28 days prior to their first medication use.
- History of immunodeficiency.
- Use of attenuated live vaccine within 28 days prior to the first study medication.
- Have undergone major surgery within 28 days prior to the first administration of medication.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SHR-A2102 + Adebrelimab Group
Treatment with SHR-A2102 in combination with a fixed dose of Adebrelimab. |
Treatment with SHR-A2102 in combination with fixed dose Adebrelimab. Treatment with SHR-A2102 in combination with fixed dose Adebrelimab. |
|
有源比较器:Preoperative Chemotherapy Group
Preoperative chemotherapy with gemcitabine and cisplatin, and postoperative nivolumab treatment for patients with high-risk recurrence. |
Gemcitabine Hydrochloride for Injection. Cisplatin Injection. Nivolumab Injection. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Phase II: pCR evaluated by researchers
大体时间:3 months after the last subject underwent RC+PLD surgery.
|
3 months after the last subject underwent RC+PLD surgery.
|
|
Phase III: EFS assessed by BICR
大体时间:5 years after the first medication of the last subject.
|
5 years after the first medication of the last subject.
|
|
Recommended Phase 3 Dose (RP3D)
大体时间:3 months after MIBC surgery.
|
3 months after MIBC surgery.
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
ORR
大体时间:From first dose to disease progression or death, whichever comes first, up to 3 years.
|
From first dose to disease progression or death, whichever comes first, up to 3 years.
|
|
DCR
大体时间:From first dose to disease progression or death, whichever comes first, up to 3 years.
|
From first dose to disease progression or death, whichever comes first, up to 3 years.
|
|
pCR
大体时间:Three months after MIBC surgery.
|
Three months after MIBC surgery.
|
|
EFS
大体时间:From first dose to disease progression or death, whichever comes first, up to 3 years.
|
From first dose to disease progression or death, whichever comes first, up to 3 years.
|
|
DFS
大体时间:From first dose to disease progression or death, whichever comes first, up to 3 years.
|
From first dose to disease progression or death, whichever comes first, up to 3 years.
|
|
OS
大体时间:From first dose to disease progression or death, whichever comes first, up to 3 years.
|
From first dose to disease progression or death, whichever comes first, up to 3 years.
|
|
Pathological downstaging (pDS)
大体时间:3 months after MIBC surgery.
|
3 months after MIBC surgery.
|
|
AE
大体时间:From Day1 to 90 days after last dose.
|
From Day1 to 90 days after last dose.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.